Novartis AG received breakthrough therapy designation from the U.S. Food and Drug Administration for an experimental treatment for advanced castration-resistant prostate cancer, the Swiss drugmaker said on June 16.


Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental tumor-targeting radiation therapy from Swiss drugmaker Novartis, data released on June 3 showed.

The U.S. Food and Drug Administration granted approval to Myfembree, Myovant Sciences and Pfizer’s once-daily treatment for heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Patients receiving the therapy under the newly approved indication can take the medicine for up to 24 months. 

Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis.

Myovant announced additional data from the company’s Phase III HERO trial of once-daily, oral relugolix in advanced prostate cancer.

Dendreon Pharmaceuticals released results of a first-of-its-kind study examining survival outcomes in men with metastatic castrate-resistant prostate cancer who were treated with PROVENGE (sipuleucel-T) and oral agents in a real-world treatment setting.